Zobrazeno 1 - 10
of 495
pro vyhledávání: '"Keunchil Park"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Sehhoon Park, Jin Seok Ahn, Jong-Mu Sun, Myung-Ju Ahn, Hyun Ae Jung, Keunchil Park, Hongsik Kim, Se-Hoon Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Metachronous brain-only oligorecurrence in patients with non–small cell lung cancer (NSCLC) is a rare event with favorable prognosis, but the clinical outcome has not been fully determined. We retrospectively analyzed clinical outcomes and
Autor:
Fred R. Hirsch, Sarah M. Paul, Keunchil Park, C. Matheny, Achim Rittmeyer, Jing Yi, Wei Zou, Marcus Ballinger, Mark McCleland, Fabrice Barlesi, Keith M. Kerr, Shirish M. Gadgeel, Hartmut Koeppen, David R. Gandara, David S. Shames, Namrata Bhatia
Publikováno v:
Clinical Lung Cancer. 23:21-33
BACKGROUND This phase III OAK trial (NCT02008227) subgroup analysis (data cutoff, January 9, 2019) evaluated the predictive value of 2 PD-L1 IHC tests (VENTANA SP142 and Dako 22C3) for benefit from atezolizumab versus docetaxel by programmed death li
Autor:
Hyun Ae Jung, Jong-Mu Sun, Cheol-In Kang, Jin Seok Ahn, Byeong-Ho Jeong, Sehhoon Park, Keunchil Park, Se-Hoon Lee, Yong-Pyo Lee, Myung-Ju Ahn, Yeonghee Eun
Publikováno v:
European Journal of Cancer. 159:167-173
Background Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined. Herein, we pr
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Publikováno v:
Future Oncology. 17:2395-2408
Few data are available that have compared outcomes with different EGFR tyrosine kinase inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell lung cancer. In this narrative review, we have collated available data
Autor:
Steve Olsen, Hyun-Ae Jung, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Min-Sang Lee, Sehhoon Park, Yoon-La Choi, Jong-Mu Sun, Bo Mi Ku, Keunchil Park
Publikováno v:
Cancer. 127:3019-3028
Background Because of the growing number of actionable biomarkers in non-small cell lung cancer (NSCLC), sufficient tissue availability for testing is becoming a greater challenge. Liquid biopsy offers a potential solution by complementing standard t
Autor:
Juliane Manitz, Fabrice Barlesi, Johan Vansteenkiste, Marcis Bajars, Mary Ruisi, Keunchil Park, Mustafa Ozguroglu, James Chih-Hsin Yang, David R. Spigel
Publikováno v:
Lung Cancer
Lung Cancer, 2021, 154, pp.92-98. ⟨10.1016/j.lungcan.2021.01.026⟩
Lung Cancer, Elsevier, 2021, 154, pp.92-98. ⟨10.1016/j.lungcan.2021.01.026⟩
Lung Cancer, 2021, 154, pp.92-98. ⟨10.1016/j.lungcan.2021.01.026⟩
Lung Cancer, Elsevier, 2021, 154, pp.92-98. ⟨10.1016/j.lungcan.2021.01.026⟩
Objectives: The JAVELIN Lung 200 phase 3 trial did not meet its primary endpoint of improving overall survival (OS) with avelumab vs docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report post hoc analyses assessing the effects of subseq
Autor:
Hannah M Davis, Jürgen Wolf, Keunchil Park, Boris Lin, Herbert H. Loong, Benjamin Solomon, Maurice Pérol, Fernando C. Santini, Victoria Soldatenkova, Alexander Drilon, Silvia Novello, Edurne Arriola, Koichi Goto, Aimee Bence Lin, C. Zhou, Yasir Elamin, Andreas Sashegyi
Publikováno v:
Future Oncology. 17:763-773
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in
Autor:
Rebecca R. Hozak, Bo H. Chao, Ling Gao, Luis Paz-Ares, David Planchard, James Chih-Hsin Yang, Sameera R. Wijayawardana, Dae Ho Lee, Huzhang Mao, Keunchil Park, Helena A. Yu, Ki Hyeong Lee, Joo Hang Kim, Pilar Garrido
Publikováno v:
Clinical Cancer Research. 27:992-1002
Purpose: We report the final analysis of JVDL (NCT02789345), which examined the combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive EGFR-mutant non–small